Metastatic Merkel Cell Carcinoma Response to Nivolumab

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2016 Nov 24

PMID 27879975

Citations 25

Authors

Frances M Walocko

Benjamin Y Scheier

Paul W Harms

Leslie A Fecher

Christopher D Lao

Affiliations

Soon will be listed here.

Abstract

Background: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy with limited treatment options. Several lines of evidence support the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis as a likely contributor to immune evasion in MCC.

Case Presentation: We report a case of a patient with metastatic MCC with a significant and durable response to nivolumab, a humanized IgG4 monoclonal anti-PD-1 antibody.

Conclusion: Immunotherapy with PD-1/PD-L1 inhibitors has become a rational and promising treatment option for MCC in the advanced or metastatic disease. Clinical trials are currently in progress to further evaluate these novel therapeutic agents.

Citing Articles

Possible association between polyomaviruses and gastrointestinal complications: a narrative review.

Shadbash P, Hosseini S, Shoraka S, Ghaemi A, Haghazali M, Mohebbi S Gastroenterol Hepatol Bed Bench. 2024; 17(2):121-131.

PMID: 38994506 PMC: 11234488. DOI: 10.22037/ghfbb.v17i2.2796.

Two primary cancers appeared after discontinuation of nivolumab in the course of treating Hodgkin lymphoma: a case report.

Potluri L, Nanjareddy S, Al Sbihi A, Manasrah N, Smith 4th W, Sano D AME Case Rep. 2023; 7:30.

PMID: 37492791 PMC: 10364003. DOI: 10.21037/acr-22-87.

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab.

Incorvaia L, Dimino A, Algeri L, Brando C, Magrin L, De Luca I Front Oncol. 2023; 13:1141500.

PMID: 37139149 PMC: 10149939. DOI: 10.3389/fonc.2023.1141500.

Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response.

Zelin E, Maronese C, Dri A, Toffoli L, Di Meo N, Nazzaro G J Clin Med. 2022; 11(12).

PMID: 35743435 PMC: 9225110. DOI: 10.3390/jcm11123364.

Merkel cell carcinoma of the eyelid and periocular region: A review.

Walsh N Saudi J Ophthalmol. 2022; 35(3):186-192.

PMID: 35601863 PMC: 9116095. DOI: 10.4103/SJOPT.SJOPT_55_21.

References

Karakousis C, Balch C, Urist M, Ross M, Smith T, Bartolucci A . Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol. 1996; 3(5):446-52. DOI: 10.1007/BF02305762. View

Feng H, Shuda M, Chang Y, Moore P . Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008; 319(5866):1096-100. PMC: 2740911. DOI: 10.1126/science.1152586. View

Nghiem P, Bhatia S, Lipson E, Kudchadkar R, Miller N, Annamalai L . PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016; 374(26):2542-52. PMC: 4927341. DOI: 10.1056/NEJMoa1603702. View

Tai P, Yu E, Winquist E, Hammond A, Stitt L, Tonita J . Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol. 2000; 18(12):2493-9. DOI: 10.1200/JCO.2000.18.12.2493. View

Bichakjian C, Lowe L, Lao C, Sandler H, Bradford C, Johnson T . Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer. 2007; 110(1):1-12. DOI: 10.1002/cncr.22765. View

Iyer J, Afanasiev O, McClurkan C, Paulson K, Nagase K, Jing L . Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res. 2011; 17(21):6671-80. PMC: 3207011. DOI: 10.1158/1078-0432.CCR-11-1513. View

Rodig S, Cheng J, Wardzala J, DoRosario A, Scanlon J, Laga A . Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest. 2012; 122(12):4645-53. PMC: 3533549. DOI: 10.1172/JCI64116. View

Kaufman H, Russell J, Hamid O, Bhatia S, Terheyden P, DAngelo S . Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016; 17(10):1374-1385. PMC: 5587154. DOI: 10.1016/S1470-2045(16)30364-3. View

Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R . Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget. 2015; 7(3):3403-15. PMC: 4823115. DOI: 10.18632/oncotarget.6494. View

10.

Paulson K, Carter J, Johnson L, Cahill K, Iyer J, Schrama D . Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res. 2010; 70(21):8388-97. PMC: 2970647. DOI: 10.1158/0008-5472.CAN-10-2128. View

11.

Frohm M, Griffith K, Harms K, Hayman J, Fullen D, Nelson C . Recurrence and Survival in Patients With Merkel Cell Carcinoma Undergoing Surgery Without Adjuvant Radiation Therapy to the Primary Site. JAMA Dermatol. 2016; 152(9):1001-7. DOI: 10.1001/jamadermatol.2016.1428. View

12.

Dowlatshahi M, Huang V, Gehad A, Jiang Y, Calarese A, Teague J . Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Invest Dermatol. 2013; 133(7):1879-89. PMC: 3691077. DOI: 10.1038/jid.2013.75. View

13.

Lipson E, Vincent J, Loyo M, Kagohara L, Luber B, Wang H . PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2014; 1(1):54-63. PMC: 3885978. DOI: 10.1158/2326-6066.CIR-13-0034. View

14.

Lewis K, Weinstock M, Weaver A, Otley C . Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol. 2006; 142(6):693-700. DOI: 10.1001/archderm.142.6.693. View

15.

Afanasiev O, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer J . Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res. 2013; 19(19):5351-60. PMC: 3790865. DOI: 10.1158/1078-0432.CCR-13-0035. View

16.

Harms P, Collie A, Hovelson D, Cani A, Verhaegen M, Patel R . Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation. Mod Pathol. 2016; 29(3):240-8. PMC: 4769666. DOI: 10.1038/modpathol.2015.154. View

17.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. PMC: 5698905. DOI: 10.1056/NEJMoa1504030. View

18.

Medina-Franco H, Urist M, Fiveash J, Heslin M, Bland K, Beenken S . Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol. 2001; 8(3):204-8. DOI: 10.1007/s10434-001-0204-4. View

19.

Cassler N, Merrill D, Bichakjian C, Brownell I . Merkel Cell Carcinoma Therapeutic Update. Curr Treat Options Oncol. 2016; 17(7):36. PMC: 5690804. DOI: 10.1007/s11864-016-0409-1. View

20.

Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz A, Henson D . Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 2009; 37(1):20-7. DOI: 10.1111/j.1600-0560.2009.01370.x. View